Congratulations - #KasiaGryglewska ‼️ We keep continuing our work on #longCovid , including hospitalized #patients at high #CVD risk‼️💪 #HeartFailure2024
Participación de nuestros facultativos y residentes del en el Congreso de Heart Failure 2024 en Lisboa! 🌍❤️
👩⚕️🧑⚕️ Ainhoa Robles Clara Jimenez Rubio Luis García Rodríguez
#HeartFailure2024 #SaludCardiovascular
escardio.org/Congresses-Eve…
#HFAmotions #HeartFailure2024 #20yearsHFA
Exciting conversation about HFA Congress with the President of the European Society of Cardiology Thomas Luscher 🤩🤩🤩
Leclercq christophe GICC Manel EL BLIDI Frederik H. Verbrugge Novi Tham
Data from #PARAGON and #PARAGLIDE showed that ARNI+MRA improved kidney outcomes in HFmrEF and HFpEF pts. Data presented by Riccardo M. Inciardi at #HeartFailure2024 🇵🇹
🔴 Antiarrhythmic Drug Classifications
#Cardioed #Cardiology #CardiogenicShock #meded #medtwitterWhat #MedTwitter #CardioEd #medx #medEd #CardioTwitter #cardiotwitter #MedX #MedEd #HeartFailure2024 #cardiology #cardiotwiteros #FOAMed
Wow, game-changing #SELECT data out at #HeartFailure2024 !
Sema 2.4mg ⬇️ CVd+HF events by 21% in HF subgroup of n=4,286
Remarkably, efficacy & safety consistent in both HFrEF & HFpEF
Supports health status gains in #STEPHFpEF & likely to have regulatory/guideline implications
May held some of the biggest heart failure, interventional, & electrophysiology cardiology meetings!
Explore the hottest science from #JACCJourals at #HeartFailure 2024 , #EuroPCR , & #HRS2024 here: bit.ly/3QYbx3d
#HeartFailure #EPeeps #cvEP #CathLab
Check out the highlights in Heart Failure for #CSANZ2024 in Perth - early-bird closing Monday 3 June. Watch video👉bit.ly/3R3AVod
Register Now!👉csanzasm.com
#CardioTwitter David Playford Dr Girish Dwivedi #heartfailure2024
👩⚕️Nuestra residente, Lucía Palma, presenta el trabajo: Clinical, prognosis and economic outcomes in a novel cardio-renal-metabolic unit en #HeartFailure2024
#HeartFailure2024
CD8+ Cytotoxic T-cells Drive Outcome in Chronic Inflammator Cardiomyopathy
unexplored role of CD8+ T-cells in InfI-CMP
Selectively targeting the CD8+ T-cell population may further benefit the treatment of Infl-CMP patients
#HeartFailure2024
EXCELLENT Phase 1/2b study: ProtheraCytes® cell therapy in Acute Myocardial Infarction
Regenerative therapy based on ProtheraCytes® injection in post-AMI emerges as innovative strategy to prevent heart failure-associated outcomes
Javed Butler C. Michael Gibson MD
#HeartFailure2024
PRAISE HFpEF DM
Glucagon-like Peptide-1 Receptor Agonist In obeSE Heart Failure with Preserved Ejection Fraction with type 2 diabetes
In DM and obese HFpEF, GLP1-RA at diabetes management associated with reduction in the composite of HFH and mortality
Aficamten for the treatment of symptomatic oHCM. A new kid in the block showing significant improvement in symptoms, exercise capacity and quality of life compared to placebo in oHCM patients 👏🏻👏🏻👏🏻 #HeartFailure2024 #sequoia_hcm European Society of Cardiology
Soon to start Highlights session at #HeartFailure2024 . Room packed. So proud to present the acute heart failure part 😃
#HeartFailure2024
Diuresis Efficacy in Ambulatory Chronic Heart Failure Patients:
Intra-Patient Comparison of Three Diuretic Regimens (DEA-HF Clinical Trial)
Intravenous furosemide plus metolazone resulted in a significantly higher natriuresis when compared to IV furosemide
Straight out of #HeartFailure2024 , it’s time to launch the #HFA_ESC #HFA_YOUNG JOURNAL CLUB
1st edition is on 5 JUNE 6PM CEST will discuss: the PUSH-AHF trial
Register now: bit.ly/44J2jxw